In contrast, Kunitz-type protease inhibitor 2 (SPINT2) and prostate cancer, as well as Semaphorin-3G (SEMA3G) and CRC, were shown to have distinct variants at the gene target (i.e. PPH3 > 0.8; Supplementary Data 6). The gene discussed is SPINT2; the disease is prostate carcinoma.